I agree with everything you said, but if you are talking long term when the IMU IP is fully developed, then $50bn don't cut it for me. Remember this, Roche paid $43bn for Herceptin and, I believe 2 other drug. If our B-Cell platform is fully developed, that alone would be worth more than $50bn, I believe. And then there is that CF33.
Bottom line, longer term, if the CF33 works as shown in the lab and cure cancers, then seriously, $100bn might not even cut it. After all, nobody knows yet what price for a cure. And that is the holy grail here for me. And more importantly, for all the cancer patients to come.
Expand
(20min delay)